Kiora Pharmaceuticals KPRX Stock
Kiora Pharmaceuticals Price Chart
Kiora Pharmaceuticals KPRX Financial and Trading Overview
| Kiora Pharmaceuticals stock price | 3.2 USD |
| Previous Close | 0.76 USD |
| Open | 0.76 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 900 |
| Day's Range | 0.76 - 0.81 USD |
| 52 Week Range | 0.73 - 20 USD |
| Volume | 404.17K USD |
| Avg. Volume | 199.16K USD |
| Market Cap | 5.07M USD |
| Beta (5Y Monthly) | 0.041549 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0.87 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46 USD |
KPRX Valuation Measures
| Enterprise Value | -1817571 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.42780748 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.15120016 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.165 |
Trading Information
Kiora Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.041549 |
| 52-Week Change | -94.87% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 20 USD |
| 52 Week Low | 0.73 USD |
| 50-Day Moving Average | 2.62 USD |
| 200-Day Moving Average | 4.49 USD |
KPRX Share Statistics
| Avg. Volume (3 month) | 199.16K USD |
| Avg. Daily Volume (10-Days) | 934.93K USD |
| Shares Outstanding | 6.34M |
| Float | 1.99M |
| Short Ratio | 3.7 |
| % Held by Insiders | 7.02% |
| % Held by Institutions | 12.57% |
| Shares Short | 183.87K |
| Short % of Float | 9.37% |
| Short % of Shares Outstanding | 9.08% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:40 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -40.47% |
| Return on Equity (ttm) | -111.025% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -11021026 USD |
| Net Income Avi to Common (ttm) | -11887132 USD |
| Diluted EPS (ttm) | -8.32 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.43M USD |
| Total Cash Per Share (mrq) | 1.69 USD |
| Total Debt (mrq) | 73.29K USD |
| Total Debt/Equity (mrq) | 0.72 USD |
| Current Ratio (mrq) | 2.606 |
| Book Value Per Share (mrq) | 5.291 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10665341 USD |
| Levered Free Cash Flow (ttm) | -7477593 USD |
Profile of Kiora Pharmaceuticals
| Country | United States |
| State | CA |
| City | Encinitas |
| Address | 332 Encinitas Boulevard |
| ZIP | 92024 |
| Phone | 781 788 8869 |
| Website | https://www.kiorapharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Q&A For Kiora Pharmaceuticals Stock
What is a current KPRX stock price?
Kiora Pharmaceuticals KPRX stock price today per share is 3.2 USD.
How to purchase Kiora Pharmaceuticals stock?
You can buy KPRX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kiora Pharmaceuticals?
The stock symbol or ticker of Kiora Pharmaceuticals is KPRX.
Which industry does the Kiora Pharmaceuticals company belong to?
The Kiora Pharmaceuticals industry is Biotechnology.
How many shares does Kiora Pharmaceuticals have in circulation?
The max supply of Kiora Pharmaceuticals shares is 3M.
What is Kiora Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Kiora Pharmaceuticals PE Ratio is 3.67816100 now.
What was Kiora Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Kiora Pharmaceuticals EPS is 0.87 USD over the trailing 12 months.
Which sector does the Kiora Pharmaceuticals company belong to?
The Kiora Pharmaceuticals sector is Healthcare.
Kiora Pharmaceuticals KPRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}